Share price · BHC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BHC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 29 Oct 2026+28.8%
- 28 Oct 2026+9.7%
- 4 Aug 2026-8.0%
Nothing announced by BHC that day or the session before.
- 31 Jul 2026+14.3%
Nothing announced by BHC that day or the session before.
- 30 Jul 2026+28.8%
- 26 Jun 2026-9.8%
Nothing announced by BHC that day or the session before.
- 17 Jun 2026-4.0%
Nothing announced by BHC that day or the session before.
- 11 May 2026-6.6%
Nothing announced by BHC that day or the session before.
- 10 Apr 2026+3.9%
Nothing announced by BHC that day or the session before.
- 23 Jan 2026-10.0%
Share of unusual movement by asset
For each asset, the share of BHC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
brodalumab (Siliq)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 40% |
| Sessions with no dated event | — | 60% |
Assets
(15 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | AminosalicylateSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
brodalumab(Siliq) | Approved | IL-17 receptor AMonoclonal antibody | Psoriasis |
| Approved | Glucocorticoid receptorSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
| Approved | Glucocorticoid receptorSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
| Approved | GABA-A receptorSmall molecule | Epilepsy | |
| Approved | 5-HT1D receptorSmall molecule | Migraine | |
| Approved | 5-HT1D receptorSmall molecule | Migraine | |
Halobetasol Propionate Lotion(Bryhali) | Approved | Glucocorticoid receptorSmall molecule | Psoriasis |
halobetasol propionate/tazarotene(Duobrii) | Approved | Glucocorticoid receptor + retinoic acid receptorSmall molecule | Psoriasis |
| Approved | AminosalicylateSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
| Approved | Mechanism not establishedSmall molecule | Epilepsy | |
| Approved | Rifamycin AntibacterialSmall molecule | Travelers' Diarrhea | |
Verteporfin(Visudyne) | Approved | Benzoporphyrin-derivative photosensitizer for photodynamic therapySmall molecule | Age-Related Macular Degeneration |
| Phase 3 | Rifamycin AntibacterialSmall molecule | Indication not yet linked | |
| Phase 2 | S1P receptorSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis, Crohn's Disease |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (18)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $2.9B | $141M | $2.5B | —$814M operating cash flow | report ↗ |
View 17 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $2.9B | $173M | $1.8B | —$670M operating cash flow | report ↗ |
| 2026-Q1 | $2.5B | $163M | $1.3B | — | report ↗ |
| 2025-Q4 | $2.8B | $161M | $1.3B | — | report ↗ |
| 2025-Q3 | $2.7B | $166M | $1.3B | — | report ↗ |
| 2025-Q2 | $2.5B | $159M | $1.7B | — | report ↗ |
| 2025-Q1 | $2.3B | $143M | $1.1B | — | report ↗ |
| 2024-Q4 | $2.6B | $163M | $1.2B | — | report ↗ |
| 2024-Q3 | $2.5B | $146M | $719M | — | report ↗ |
| 2024-Q2 | $2.4B | $156M | $595M | — | report ↗ |
| 2024-Q1 | $2.2B | $151M | $755M | $64M$211M operating cash flow | report ↗ |
| 2023-Q3 | $2.2B | $153M | $780M | $378M$282M operating cash flow | report ↗ |
| 2023-Q2 | $2.2B | $156M | $588M | —$206M operating cash flow | report ↗ |
| 2023-Q1 | $1.9B | $143M | $531M | $201M$154M operating cash flow | report ↗ |
| 2022-Q3 | $2.0B | $133M | $497M | —-$1.3B operating cash flow | report ↗ |
| 2022-Q2 | $2.0B | $127M | $1.9B | $145M$123M operating cash flow | report ↗ |
| 2022-Q1 | $1.9B | $127M | $2.5B | $69M-$63M operating cash flow | report ↗ |
| 2021-Q3 | $2.1B | $121M | $1.9B | —$564M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $10.3B | $629M | $1.3B | — | report ↗ |
Bausch Health reported full-year 2025 revenue of $10,266M, up 6.7% YoY, with R&D spend of $629M, up 2.1% YoY, cash and equivalents of $1,310M, and net income attributable to Bausch Health of $157M. The company also reported consolidated adjusted EBITDA attributable to Bausch Health of $3.54 billion for the year, up 7%.
For 2026, the company guided to revenues of $10.625–$10.875 billion, adjusted EBITDA of $3.875–$4.000 billion, and adjusted operating cash flow of $1.200–$1.275 billion. Pipeline updates included FDA Breakthrough Therapy Designation for larsucosterol and initiation of its Phase 3 trial in January 2026, Australian approval of the Fraxel FTX laser system, and RED-C Phase 3 studies that did not achieve their primary endpoint. Key disclosed events included the completion of the Shibo aesthetics distribution acquisition in China and $9.6 billion in total 2025 refinancing, including a $1.7 billion debt exchange in the fourth quarter.
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($15.6M), 5 sales ($507K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-30 | WECHSLER AMY B · director | Award / grant | 1,179 | $5.83 | $7K | Form 4 |
| 2026-09-30 | LEUNG SANDRA · director | Award / grant | 5,789 | $5.83 | $34K | Form 4 |
| 2026-09-30 | Paulson John · director | Award / grant | 10,720 | $5.83 | $62K | Form 4 |
| 2026-08-19 | Lenar Aimee J. · President, US Pharma | Open-market sale | 36,827 | $7.03 | $259K | Form 4 |
| 2026-07-17 | Lenar Aimee J. · President, US Pharma | Tax withholding | 5,260 | $4.83 | $25K | Form 4 |
| 2026-07-15 | Lenar Aimee J. · President, US Pharma | Tax withholding | 23,395 | $4.89 | $114K | Form 4 |
| 2026-07-14 | LEE STEVEN HYOSIG · SVP, Controller & CAO | Tax withholding | 3,125 | $4.75 | $15K | Form 4 |
| 2026-06-30 | LEUNG SANDRA · director | Award / grant | 6,845 | $4.93 | $34K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 226 reporting institutions held 232.6M shares ($1.2B, 62.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | PAULSON & CO. INC. | 73,255,869 | $395.6M |
| 2 | GOLDENTREE ASSET MANAGEMENT LP | 34,665,731 | $187.0M |
| 3 | ROYAL BANK OF CANADA | 11,363,498 | $61.4M |
| 4 | NOMURA HOLDINGS INC | 8,986,372 | $48.5M |
| 5 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 8,000,000 | $43.2M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 7,403,759 | $40.0M |
| 7 | MFN Partners Management, LP | 6,000,000 | $32.4M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 4,228,871 | $31.4M |
| 9 | Kohlberg Kravis Roberts & Co. L.P. | 5,235,000 | $28.3M |
| 10 | GOLDMAN SACHS GROUP INC | 5,207,966 | $28.1M |
| 11 | Hudson Bay Capital Management LP | 5,000,000 | $27.0M |
| 12 | ING GROEP NV | 5,000,000 | $27.0M |
| 13 | Nuveen, LLC | 3,798,957 | $20.5M |
| 14 | DIMENSIONAL FUND ADVISORS LP | 3,604,818 | $19.5M |
| 15 | MACQUARIE GROUP LTD | 3,250,000 | $17.6M |